ODI Pharma AB (ODI.ST) Stock Analysis & Winston Score

ODI Pharma AB is a Swedish pharmaceutical company that makes and sells cannabis-based medicines. It focuses on medical cannabis products, including oils, capsules, and other formats, sold to patients and healthcare providers primarily in Europe. The company operates in the growing but tightly regulated market for prescription medical cannabis. ODI Pharma earns revenue by selling its products directly through pharmacies and healthcare channels, rather than through subscriptions or software. It is a small company, with a market cap around $0.1 billion, and operates mainly in Sweden and select European markets where medical cannabis is legal. Its relatively high return on invested capital suggests efficient use of resources, but its thin gross margin of 14% points to real cost pressures in manufacturing and distribution. The key growth driver is expanding access to medical cannabis across Europe as more countries legalize it for prescription use, while the main risk is heavy dependence on shifting regulations that could restrict sales at any time.